
Thermo Fisher Scientific Inc.
TMO 578.71 (-0.24%) 1.42
Health Care
Life Sciences Tools and Services
Quality Checklist 5/8
5Y Shares Out Change < 0%
Debt/Equity < 1
Current Ratio > 1
Net Margin > 10%
Est. EPS Growth > 5%
ROIC > 10%
Quick Ratio > 1
Past Net Income CAGR > 0%
0.0%of Portfolio
My holdings
Day change:
Total change:
Shares:Cost basis:
Market cap: $217.43(B)
EV: $249.70(B)
Total Equity: $51.15(B)
Earnings date: Jan-29-2026
P/E: 33.37
Forward P/E: 25.46
P/FCF: 35.57
P/S: 5.01
P/B: 4.26
EPS: $17.3
EPS (fwd): $22.7
FCF/share: $16.3
Revenue/share: $115.4
Book value/share: $135.8
ROIC: 7.7%
ROA: 6.5%
ROE: 13.1%
Debt/Equity: 0.70
Current Ratio: 1.50
Gross margin: 41.4%
Operating margin: 18.4%
Net margin: 15.0%
Dividend/share: $1.7
Div. yield: 0.29%
TMO Valuation & Price Targets
Current Price
$579
Favorite Valuation Methods
More Valuation Methods
DCF (simple)
N/A
N/A
DCF (exit mult.)
N/A
N/A
DDM
N/A
N/A
EPS growth
N/A
N/A
Revenue growth
N/A
N/A
Peter Lynch FV
N/A
N/A
Graham No.
N/A
N/A
PEvaluation
37% overvalued
Low
$272
Mid
$363
High
$453
Current price
$579
Fair P/E
Margin of safety
EPS
Market Model
Economic moat: Medium
EPS Estimates
| Low | Avg | High | # | |
| FY+1 | 22.5 | 22.7 | 22.8 | 25 |
| FY+2 | 24.0 | 24.6 | 25.9 | 26 |
| FY+3 | 26.1 | 27.2 | 28.4 | 16 |
| FY+4 | 30.0 | 30.7 | 32.3 | 5 |
| FY+5 | 32.4 | 34.3 | 36.9 | 3 |
Analyst Price Targets
7% undervalued
Low
$533
Mid
$620
High
$675
Current price
$579
Analyst Recommendations
2-stage DCF
First Stage Duration: 5 Years | |
| Starting Free Cash Flow | |
First Stage Growth Rate | |
LowMidHigh | |
Terminal Growth Rate | |
LowMidHigh | |
| Discount Rate | |
Discounted Cash Flow
Forecast years: 5 Years | |
Terminal Growth Rate | |
LowMidHigh | |
| Discount Rate | |
Free cash flow estimates:
Discounted Cash Flow (exit mult.)
Forecast years: 5 Years | |
Exit FCF Multiple | |
LowMidHigh | |
| Discount Rate | |
Free cash flow estimates:
Dividend Discount Model
| Annual Dividend | |
First Stage Length (Years): 0 Years | |
| First Stage Growth Rate | |
| Final Growth Rate | |
| Discount Rate | |
EPS Growth
Forecast years: 5 Years | |
| Starting EPS | |
EPS Growth Rate | |
LowMidHigh | |
Final P/E | |
LowMidHigh | |
| Discount Rate | |
Revenue Growth Valuation
Forecast Years: 10 Years | |
| Base Revenue | |
Revenue Growth Rate | |
LowMidHigh | |
Final Net Margin | |
LowMidHigh | |
Final P/E Ratio | |
LowMidHigh | |
| Discount Rate | |
Peter Lynch Fair Value
| Earnings Per Share | |
| Growth Rate |
Graham Formula
| Earnings Per Share | |
| EPS Growth (7-10 years) | |
| Government Bond Rate |
